Rx Act Nasal Original label

Rx Act Nasal Original

Rx Act Nasal Original Recall

Get an alert when a recall is issued.

Side Effects & Adverse Reactions

There is currently no warning information available for this product. We apologize for any inconvenience.

FDA Safety Alerts

There are currently no FDA safety alerts available for this drug.

Manufacturer Warnings

There is currently no manufacturer warning information available for this drug.

FDA Labeling Changes

There are currently no FDA labeling changes available for this drug.

Uses

Choline C 11 Injection is indicated for positron emission tomography (PET) imaging of patients with suspected prostate cancer recurrence and non-informative bone scintigraphy, computerized tomography (CT) or magnetic resonance imaging (MRI). In these patients, 11 C-choline PET imaging may help identify potential sites of prostate cancer recurrence for subsequent histologic confirmation. Suspected prostate recurrence is based upon elevated blood prostate specific antigen (PSA) levels following initial therapy. In clinical studies, images were produced with PET/CT coregistration.

Limitation of Use: 11 C-choline PET imaging is not a replacement for histologic verification of recurrent prostate cancer.

History

There is currently no drug history available for this drug.

Other Information

11.1       Chemical Characteristics

Choline C 11 Injection is a positron emitting radiopharmaceutical that is used for diagnostic purposes in conjunction with PET imaging.  The active ingredient, 11C-choline, has the molecular formula of C411CH14 NOCl with a molecular weight of 138.63 g and has the following chemical structure:

Choline C 11 chemical structure

Choline C 11 Injection is provided as a ready to use sterile, pyrogen-free, clear and colorless solution.  Each milliliter contains 148 – 1,225 MBq (4 – 33.1 mCi) of 11C-choline at EOS calibration time in aqueous 0.9% sodium chloride solution.  The pH of the solution is between 4.5 and 7.5.  

11.2       Physical Characteristics

Carbon 11 is a cyclotron-produced radionuclide that decays to Boron 11 by positron emission and has a physical half life of 20.4 minutes (Table 2).

Table 2: Principal Radiation Emission Data for 11C
 Radiation/Emission  % Per Disintegration  Energy
 Positron (β+)  99.76  960.2 keV (Max.)
 Gamma (±)*  199.5  511 keV

*Produced by positron annihilation

The specific gamma ray constant (point source air kerma coefficient) for 11C-choline is 5.8 R/mCi-hr at 1 cm.  Selected coefficients of attenuation are listed in Table 3 as a function of lead shield thickness.  For example, the use of 39 mm thickness of lead will attenuate the external radiation by a factor of about 1,000. 

Table 3: Radiation Attenuation of 511 keV Photons by lead (Pb) shielding
 Shield Thickness (Pb) mm  Coefficient of Attenuation
 4  0.5
 8  0.25
 13  0.1
 26  0.01
 39   0.001
 52  0.0001

Table 4 lists fractions remaining at selected time intervals from the calibration time.  This information may be used to correct for physical decay of the radionuclide.

Table 4: Physical Decay Chart for 11C 
 Minutes  Fraction Remaining
 0*  1.000
 5  0.844 
 10  0.712 
 15  0.600 
 20  0.507 
 25  0.427 
 30  0.360 

*Calibration time

Rx Act Nasal Original Manufacturers

  • Rx Act Nasal Original | Mayo Clinic
    No Recall

    Rx Act Nasal Original | Mayo Clinic

    Rx Act Nasal Original | Mayo Clinic
    2.1       Radiation Safety - Drug Handling

    Choline C 11 Injection is a radioactive drug and should be handled with appropriate safety measures to minimize radiation exposure during administration. Use waterproof gloves and effective shielding when handling Choline C 11 Injection. Radiopharmaceuticals, including Choline C 11 Injection, should only be used by or under the control of physicians who are qualified by specific training and experience in the safe use and handling of radioactive materials, and whose experience and training have been approved by the appropriate governmental agency authorized to license the use of radionuclides.

    2.2       Recommended Dose and Administration Instructions

    The recommended dose is 370 – 740 MBq (10 – 20 mCi) administered as a bolus intravenous injection. The radioactivity dose (370 – 740 MBq, 10 – 20 mCi) is chosen based on patient body dimensions and the characteristics of the image acquisition system  

    Inspect Choline C 11 Injection visually for particulate matter and discoloration before administration. Do not use the drug if the solution contains particulate matter or is discolored. 
    Aseptically withdraw Choline C 11 Injection from its container and administer the drug as a bolus through a peripheral venous catheter. 
    Dispose of any unused drug in a safe manner, in compliance with applicable regulations.  2.3       Patient Preparation

    Prior to administration of Choline C 11 Injection:

    Fasting for at least six hours is recommended to minimize the potential for dietary choline interference with radioactivity uptake in tissue.
    Ensure that the patient is well hydrated and encourage voiding when imaging is completed.    2.4       Radiation Dosimetry

    The estimated radiation absorbed doses for adults from intravenous injection of Choline C 11 Injection are shown in Table 1.  These estimates are calculated from data in Tolvanen 1and using OLINDA/EXM (Organ Level Internal Dose Assessment/Exponential Modeling) software from Vanderbilt University.2

    Table 1: Estimated Radiation Absorbed Dose Per Unit Activity for Adults, Choline C 11 Injection  Organ/Tissue  Mean Absorbed Dose Per Unit Administered Activity (μGy/MBq)b  Adrenals  3.59  Bone – Osteogenic Cells   4.81  Bone – Red Marrow  1.90  Brain  1.16  Breast  1.39  Gallbladder Wall  4.54  GIa – Lower Large Intestine Wall   1.81  GIa – Small Intestine  2.35  GIa – Stomach Wall  6.00  GIa – Upper Large Intestine Wall   6.41  Heart wall  3.43  Kidneys  20.62  Liver  20.11  Lungs  4.59  Muscle  2.54  Ovaries  2.02  Pancreas  29.19  Skin  1.22  Spleen  9.16  Testes  1.36  Thymus  1.69  Thyroid  1.49  Urinary Bladder Wall  3.41  Uterus  1.96  Total body  2.97  Effective Dose (μSv/MBq)c  4.35

    a Gastrointestinal
    b Assumed radiation weighting factor, wr, (formerly defined as quality factor, Q) of 1 for conversion of absorbed dose (Gray or rad) to dose equivalent (Sieverts or rem) for C 11. To obtain radiation absorbed dose in rad/mCi from the above table, multiply the dose in μGy/MBq by 0.0037, (e.g., 3.59 μGy/MBq × 0.0037 = 0.0133 rad/mCi).
    c Radiation tissue weighting factors, wT, used in the calculation of effective dose are from 1990 Recommendations of the International Commission on Radiological Protection, ICRP Publication 60 (1991). To obtain radiation absorbed dose in rem/mCi from above table, multiply the dose in μGy/MBq by 0.0037, (e.g., 4.35 μGy/MBq × 0.0037 = 0.0161 rem/mCi).

    The effective dose resulting from a 740 MBq (20 mCi) dosage of Choline C 11 Injection is 3.22 mSv in an adult, (740 × 4.35 = 3219 μSv = 3.2 mSv). The use of a CT scan to calculate attenuation correction for reconstruction of 11C-choline images (as done in PET/CT imaging) will add radiation exposure. Based upon current scanning techniques, an effective dose of 5.8 mSv would be added from CT scanning. The actual radiation dose is operator, scanner, and patient dependent. The total radiation exposure from 11C-choline administration and subsequent scan on a PET/CT scanner is estimated to be 9.0 mSv (3.2 mSv + 5.8 mSv).

    2.5       Imaging Guidelines Initiate image acquisition immediately after administration of Choline C 11 Injection.  Imaging is typically performed from the base of the pelvis to the base of the skull.
    Acquire static emission images 0 – 15 minutes from the time of injection.
    Localized uptake of 11C-choline in a site suspicious for prostate cancer recurrence (a positive image) is determined by comparison of the anatomical relationship of concentrated radioactivity to the neighboring tissue background, exclusive of the radioactivity physiologically accumulated within the pancreas, liver, spleen, kidney and colon.